Fig. 3
From: Nanobody-based pannexin1 channel inhibitors reduce inflammation in acute liver injury
In vivo biodistribution of Panx1-targeting nanobodies. a Nb1, Nb3, Nb9 and non-targeting Nb were radiolabeled with Technetium-99m (99mTc), and 5 µg of radiolabeled nanobody was injected intravenously in healthy adult mice. SPECT/CT imaging was performed 1 h after injection. Biodistribution of nanobodies was determined by γ-counting of stomach and salivary glands and expressed as percentage of injected activity per gram of organ (n = 3 animals per group). All data was analysed by parametric 1-way analysis of variance followed by post hoc tests with Bonferroni’s correction. Data were expressed as means ± S.D. b Stomach and salivary gland sections were subjected to (1) immunohistochemistry analysis of Panx1 (green) with nuclear counterstaining (blue). For (2) negative controls, the primary antibody directed against Panx1 was omitted. Scale bars represent 100 or 250 µm (red). Representative data of 3 independent experiments